Evidence map›Paper›PMID 32366260›Full record

Trial reportJournal of hematology & oncology2020

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.

Houli Zhao, Jieping Wei, Guoqing Wei, Yi Luo, Jimin Shi, Qu Cui, Mingfeng Zhao, Aibin Liang, Qing Zhang, Jianmin Yang and 23 more

Open access · goldAbstract readClinical TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of hematology & oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 4 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. [Treatment strategies and prognostic factors for relapsed childhood acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 17 institutions in 3 countries.

Houli ZhaoBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Jieping WeiBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Guoqing WeiBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Yi LuoBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Jimin ShiBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Qu CuiDepartment of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Mingfeng ZhaoDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Aibin LiangDepartment of Hematology, Shanghai Tongji Hospital, Shanghai, China.
Qing ZhangDepartment of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China.
Jianmin YangDepartment of Hematology, Changhai Hospital of Shanghai, Shanghai, China.
Xin LiDepartment of Hematology, Xiangya Third Hospital, Changsha, China.
Jing ChenDepartment of Hematology, Shanghai Children's Medical Center, Shanghai, China.
Xianmin SongDepartment of Hematology, Shanghai General Hospital, Shanghai, China.
Hongmei JingDepartment of Hematology, Peking University Third Hospital, Beijing, China.
Yuhua LiDepartment of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Siguo HaoDepartment of Hematology, Xinhua Hospital of Shanghai, Shanghai, China.
Wenjun WuBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Yamin TanBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Jian YuBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Yanmin ZhaoBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Xiaoyu LaiBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Elaine Tan Su YinBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China.
Yunxiong WeiDepartment of Hematology, Tianjin First Central Hospital, Tianjin, China.
Ping LiDepartment of Hematology, Shanghai Tongji Hospital, Shanghai, China.
Jing HuangDepartment of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China.
Tao WangDepartment of Hematology, Changhai Hospital of Shanghai, Shanghai, China.
Didier BlaiseInstitut Paoli-Calmettes, Marseille, France.
Lei XiaoInnovative Cellular Therapeutics Co, Ltd, Shanghai, China.
Alex H ChangShanghai YaKe Biotechnology Ltd, Shanghai, China.
Arnon NaglerHematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Mohamad MohtySorbonne University, Saint-Antoine Hospital, INSERM UMRs 938, Paris, France. mohamad.mohty@inserm.fr.
He HuangBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China. huanghe@zju.edu.cn.
Yongxian HuBone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, No.79 Qingchun Road, Hangzhou, China. 1313016@zju.edu.cn.
Zhejiang University · CNGuangdong Provincial People's Hospital · CNSecond Military Medical University · CNTianjin First Center Hospital · CNTongji Hospital · CNCapital Medical University · CNCentral South University · CNInserm · FRInstitut Paoli-Calmettes · FRPeking University · CNShanghai Cell Therapy Research Institute · CNShanghai Children's Medical Center · CNShanghai First People's Hospital · CNSheba Medical Center · ILXinHua Hospital · CNZhejiang University-University of Edinburgh Institute · CNZhujiang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConsolidative allogeneic hematopoietic stem cell transplantation is a controversial option for patients with relapsed/refractory acute lymphoblastic leukemia after chimeric antigen receptor T cell (CAR-T) therapy. We performed a multicenter retrospective study to assess whether patients can benefit from haploidentical hematopoietic stem cell transplantation after CAR-T therapy.

methodsA total of 122 patients after CAR-T therapy were enrolled, including 67 patients without subsequent transplantation (non-transplant group) and 55 patients with subsequent haploidentical hematopoietic stem cell transplantation (transplant group). Long-term outcome was assessed, as was its association with baseline patient characteristics.

resultsCompared with the non-transplant group, transplantation recipients had a higher 2-year overall survival (OS; 77.0% versus 36.4%; P < 0.001) and leukemia-free survival (LFS; 65.6% versus 32.8%; P < 0.001). Multivariate analysis showed that minimal residual disease (MRD) positivity at transplantation is an independent factor associated with poor LFS (P = 0.005), OS (P = 0.035), and high cumulative incidence rate of relapse (P = 0.045). Pre-transplant MRD-negative recipients (MRD- group) had a lower cumulative incidence of relapse (17.3%) than those in the non-transplant group (67.2%; P < 0.001) and pre-transplant MRD-positive recipients (MRD+ group) (65.8%; P = 0.006). The cumulative incidence of relapse in MRD+ and non-transplant groups did not differ significantly (P = 0.139). The 2-year LFS in the non-transplant, MRD+, and MRD- groups was 32.8%, 27.6%, and 76.1%, respectively. The MRD- group had a higher LFS than the non-transplantation group (P < 0.001) and MRD+ group (P = 0.007), whereas the LFS in the MRD+ and non-transplant groups did not differ significantly (P = 0.305). The 2-year OS of the MRD- group was higher than that of the non-transplant group (83.3% versus 36.4%; P < 0.001) but did not differ from that of the MRD+ group (83.3% versus 62.7%; P = 0.069). The OS in the non-transplant and MRD+ groups did not differ significantly (P = 0.231).

conclusionHaploidentical hematopoietic stem cell transplantation with pre-transplant MRD negativity after CAR-T therapy could greatly improve LFS and OS in patients with relapsed/refractory acute lymphoblastic leukemia.

trial registrationThe study was registered in the Chinese clinical trial registry (ChiCTR1900023957).

Indexed as

AdolescentAdultChildFemaleHematopoietic Stem Cell TransplantationHumansImmunotherapy, AdoptiveMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaPrognosisRetrospective StudiesTransplantation, HaploidenticalTreatment OutcomeChimeric antigen receptor T cell therapyHaploidentical hematopoietic stem cell transplantationLeukemia-free survivalMinimal residual disease negativityOverall survivalRelapsed/refractory acute lymphoblastic leukemia

Identifiers

PMID32366260
PMCPMC7199358
OpenAlexW3021616332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.